Cerus lures TriVascular’s Jayaraman for CCO spot
Prior to his time at TriVascular, which was bought by Endologix (NSDQ:ELGX) earlier in the year, Jayarman held multiple positions at Medtronic (NYSE:MDT), including veep of global marketing for the company’s endovascular innovations business.
“I am pleased to add Vivek to the Cerus team. With our progress to date with U.S. blood centers, including the American Red Cross, and preparation for our European launch of the Intercept red cell system, it is now time to strengthen our global commercial leadership. Vivek has an impressive track record of success in both large and small organizations and possesses firsthand knowledge of what it takes to scale commercially. We look forward to the many contributions Vivek will bring to our mission of making Intercept the global standard of care in transfusion medicine,” CEO William Greenman said in a press release.
“This is a great time to join Cerus, and I look forward to furthering the commercial success of Intercept platelets and plasma, and preparing for the planned launch of Intercept red cells. In light of events across the globe and concerns about blood safety, the corresponding need for Intercept has never been greater. I am excited to work with the team to ensure that blood centers, hospitals, physicians and patients have access to Intercept-treated blood components,” Jayaraman said in a prepared statement.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.